A0A6D2Y6S1 (A0A6D2Y6S1_PANTR) Pan troglodytes (Chimpanzee)
Apoptosis regulator Bcl-2 UniProtKBInterProInteractive Modelling
Available Structures
52 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Bcl-2 complex with Beclin 1 BH3 domain |
Heteromer P10415; Q14457; | 100.0 | ||||
| Bcl-2 complex with Beclin 1 T108D BH3 domain |
Heteromer P10415; Q07817; Q14457; | 100.0 | ||||
| Bcl2-inhibitor complex |
Heteromer P10415; | 100.0 | ||||
| E3:PROTAC:target ternary complex structure (VCB/753b/BCL-2) |
Heteromer P10415; P40337; Q15369; Q15370; | 100.0 | 1×YF8; | |||
| Bcl-2 complex with Beclin 1 BH3 domain |
Heteromer P10415; Q14457; | 100.0 | ||||
| Crystal structure of Bcl-2 in complex with HBx-BH3 motif |
Heteromer P10415; Q99HR6; | 96.55 | ||||
| Bcl-2 alpha beta-1 LINEAR complex |
Heteromer O43521; P10415; Q07817; | 100.0 | ||||
| Crystal structure of a computationally designed protein (LD3) in complex with BCL-2 |
Heteromer P02649; P10415; | 100.0 | 2×SO4; | |||
| Crystal structure of BCL-2 in complex with a BAX BH3 peptide |
Heteromer P10415; Q07813; | 100.0 | ||||
| Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival protei… |
Heteromer P10415; Q07817; Q96LC9; | 100.0 | ||||
| E3:PROTAC:target ternary complex structure (VCB/WH244/BCL-2) |
Heteromer P10415; P40337; Q15369; Q15370; | 98.58 | 1×YFH; | |||
| Bcl-2 alpha beta-1 complex |
Heteromer O43521; P10415; Q07817; | 100.0 | ||||
| Structure of human Bcl-2 in complex with PUMA BH3 peptide |
Heteromer P10415; Q07817; Q9BXH1; | 100 | ||||
| Crystal structure of p53/BCL2 fusion complex(complex3) |
Heteromer P04637; P10415; | 95.45 | 1×ZN; | |||
| Crystal structure of p53/BCL2 fusion complex (complex 2) |
Heteromer P04637; P10415; | 95.65 | 1×ZN; | |||
| Crystal structure of p53/BCL2 fusion complex (complex 1) |
Heteromer P04637; P10415; | 95.65 | 1×ZN; | |||
| Bcl-2-xL complexed with compound 35 | monomer | 100 | 1×ULL; | |||
| Solution structure of the anti-apoptotic protein Bcl-2 complexed with an acyl-sulfonamide-based lig… | monomer | 100 | 1×43B; | |||
| Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based li… | monomer | 100 | 1×LIU; | |||
| HUMAN BCL-2, ISOFORM 1 | monomer | 100 | ||||
| Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based li… | monomer | 100 | 1×43B; | |||
| HUMAN BCL-2, ISOFORM 2 | monomer | 100 | ||||
| Crystal structure of Bcl2 in complex with S-10r | monomer | 100 | 1×N2L; | |||
| Crystal structure of Bcl2 in complex with S-9c | monomer | 100.0 | 1×MWH; | |||
| Bcl_2-Navitoclax Analog (without Thiophenyl) Complex | monomer | 100.0 | 1×1XV; | |||
| Crystal Structure of Chimaeric Bcl2-xL and Phenyl Tetrahydroisoquinoline Amide Complex | monomer | 100.0 | 1×DRO; | |||
| Human Bcl-2/Bcl-xL Chimera Fused to MBP in Complex with Inhibitor S55746 | monomer | 100.0 | 1×F3Q; 1×PEG; | |||
| Bcl_2-Navitoclax Analog (with Indole) Complex | monomer | 100.0 | 1×1Y1; | |||
| Crystal Structure Analysis of cp1 bound BCL2 | monomer | 100.0 | 1×JFF; | |||
| Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based li… | monomer | 96.0 | 1×LI0; | |||
| crystal structure of BCL-2 F104L mutation with venetoclax | monomer | 100 | 1×LBM; 4×PEG; | |||
| Human Bcl-2 (G101V Mutant)/Bcl-xL Chimera Fused to Maltose-Binding Protein | monomer | 100.0 | ||||
| Crystal structure of Bcl-2 in complex with sonrotoclax | monomer | 100 | 1×98I; | |||
| Crystal structure analysis of cp1 bound BCL2/G101V | monomer | 100.0 | 1×JFF; | |||
| Bcl_2-Navitoclax (ABT-263) Complex | monomer | 100.0 | 1×1XJ; | |||
| Crystal structure of Bcl-2 in complex with prodrug ABBV-167 | monomer | 95.45 | 1×XZD; | |||
| Crystal Structure of human Bcl-2 in complex with a small molecule inhibitor targeting Bcl-2 BH3 dom… | monomer | 100.0 | 1×1E9; | |||
| Crystal structure of Bcl-2 D103Y in complex with sonrotoclax | monomer | 100.0 | 1×98I; | |||
| Crystal structure of Bcl-2 in complex with the novel orally active inhibitor S55746 | monomer | 100 | 1×F3Q; | |||
| crystal structure of BCL-2 with venetoclax | monomer | 100 | 1×LBM; 1×2PE; | |||
| crystal structure of BCL-2 G101A mutation with venetoclax | monomer | 100 | 1×LBM; 3×PEG; | |||
| Crystal structure of Bcl-2 G101V in complex with sonrotoclax | monomer | 100.0 | 1×98I; | |||
| crystal structure of BCL-2 G101V mutation with S55746 | monomer | 100.0 | 1×F3Q; | |||
| Human Bcl-2/Bcl-xL Chimera Fused to Maltose-Binding Protein | monomer | 100.0 | ||||
| crystal structure of BCL-2 G101V mutation with venetoclax | monomer | 100.0 | 1×LBM; 2×PEG; 1×CL; | |||
| Human Bcl-2 (G101V Mutant)/Bcl-xL Chimera Fused to MBP in Complex with Inhibitor S55746 | monomer | 100.0 | 1×F3Q; 1×PEG; | |||
| HUMAN BCL-2 WITH PHENYLACYLSULFONAMIDE INHIBITOR | monomer | 100.0 | 1×398; | |||
| Structure of human Bcl-2 in complex with analogue of ABT-737 | monomer | 100 | 1×J1H; | |||
| Structure of human Bcl-2 in complex with THIQ-phenyl pyrazole compound | monomer | 100 | 1×J1Q; 1×ACT; | |||
| Structure of human Bcl-2 in complex with ABT-263 | monomer | 100 | 1×1XJ; | |||
| anti-apoptotic protein BCL-2-M12 | monomer | 100 | 1×IQ8; | |||
| Structure of human Bcl-2 in complex with fragment/ABT-263 hybrid | monomer | 100 | 1×J1T; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8fy1.1.D | monomer | 0.65 | 100.00 | |||
| 8u27.1.A | monomer | 0.56 | 91.23 | |||